Salesforce has 'gone on a diet' on M&A: Analyst

Salesforce's (CRM) better-than-expected second quarter results and raised outlook send shares higher in early trading. Jefferies Senior Analyst Brent Thill says the company has trimmed some of its costs, resulting in a "material outperformance in margin." When it comes to AI, Thills says "they're a little behind. You're going to see the revenue from that have a bigger impact in 2024." Thill also highlights Salesforce cutting back on M&A. "They were hooked on a drug called M&A and they had to go to rehab," Thill tells Yahoo Finance Live, adding that the company could make some "tactical acquisitions" to fill out its portfolio.